EUCTR2004-002267-24-IT进行中（未招募）不适用
Assessment of Everolimus in addition to Calcineurin Inhibitors Reduction in Mainteinance Renal Transplant Recipients ? ASCERTAI
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 483
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN) - ASCERTAIRenal transplantationMedDRA version: M15Classification code 10023438EUCTR2004-002267-24-CZovartis Pharma AG490
进行中（未招募）
不适用
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN) - ASCERTAIEUCTR2004-002267-24-HUovartis Pharma AG384
进行中（未招募）
不适用
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN) - ASCERTAIRenal transplantationMedDRA version: M15Classification code 10023438EUCTR2004-002267-24-ESovartis Pharma AG483
进行中（未招募）
不适用
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN) - ASCERTAIRenal transplantationMedDRA version: M15Classification code 10023438EUCTR2004-002267-24-FIovartis Pharma Services AG483
进行中（未招募）
不适用
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN) - ASCERTAIRenal transplantationMedDRA version: M15Classification code 10023438EUCTR2004-002267-24-DKovartis Pharma Services AG384